A multicenter, open-label, two-step, phase Ia/Ib study of tumor-targeted prodrug RS-0139 in patients with recurrent, locally advanced or metastatic non-small cell lung cancer (NSCLC) STUDY NUMBER: RS-001 (Phase Ia)